Oxacillin

Identification

Summary

Oxacillin is a penicillin antibiotic used to treat a number of susceptible bacterial infections.

Generic Name
Oxacillin
DrugBank Accession Number
DB00713
Background

An antibiotic similar to flucloxacillin used in resistant staphylococci infections.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 401.436
Monoisotopic: 401.104541423
Chemical Formula
C19H19N3O5S
Synonyms
  • (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
  • (5-methyl-3-phenyl-4-isoxazolyl)penicillin
  • 5-methyl-3-phenyl-4-isoxazolyl-penicillin
  • 6β-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid
  • Ossacillina
  • Oxacilina
  • Oxacillin
  • Oxacilline
  • Oxacillinum
  • Oxazocillin
  • Oxazocilline
External IDs
  • AB 1400
  • BRL 1400
  • P 12
  • SQ 16423

Pharmacology

Indication

Used in the treatment of resistant staphylococci infections.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofCatheter related infections••• •••••
Treatment ofCommunity acquired pneumonia••• •••••
Treatment ofInfections caused by penicillinase-producing staphylococci••••••••••••
Treatment ofNecrotizing soft tissue infection••• •••••
Treatment ofSurgical site infections••• •••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Oxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Oxacillin results from the inhibition of cell wall synthesis and is mediated through Oxacillin binding to penicillin binding proteins (PBPs). Oxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.

Mechanism of action

By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Oxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Oxacillin interferes with an autolysin inhibitor.

TargetActionsOrganism
APenicillin-binding protein 3
inhibitor
Streptococcus pneumoniae
APenicillin-binding protein 2a
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 1A
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 2B
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 1b
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 1A
inhibitor
Clostridium perfringens (strain 13 / Type A)
USolute carrier family 15 member 1Not AvailableHumans
UPenicillin-binding protein 2Not AvailableStaphylococcus aureus
USolute carrier family 15 member 2Not AvailableHumans
UBeta-lactamase Toho-1
substrate
Escherichia coli
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

94.2 +/- 2.1% (binds to serum protein, mainly albumin)

Metabolism
Not Available
Route of elimination

Oxacillin Sodium is rapidly excreted as unchanged drug in the urine by glomerular filtration and active tubular secretion.

Half-life

20 to 30 minutes

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirOxacillin may decrease the excretion rate of Abacavir which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Oxacillin which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Oxacillin which could result in a higher serum level.
AcenocoumarolOxacillin may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenAcetaminophen may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Oxacillin sodium4TWD2995UP1173-88-2VDUVBBMAXXHEQP-SLINCCQESA-M
Oxacillin sodium monohydrateG0V6C994Q57240-38-2ZVIYWUUZWWBNMB-VICXVTCVSA-M
International/Other Brands
Bactocill (Baxter Healthcare) / Biocilina (Biogalenic) / Bristopen (Bristol-Myers Squibb) / Dicloxal Ox (Magma) / InfectoStaph (Infectopharm) / Ocillina (CCPC) / Oxacil (Unimed) / Oxacilina (Billi Farmacêutica) / Oxacilinã (Antibiotice) / Oxagram (Medicef) / Oxal (Endure Medical) / Oxamicin (Ronava) / Oxapen (Biolab) / Oxipen (Behrens) / Panadox (Shijiazhuang) / Penstapho (Bristol-Myers Squibb) / Prostafilina (Bristol-Myers Squibb) / Prostaphlin (Bristol-Myers Squibb) / Stafcil (Aurobindo) / Staficilin-N (Bristol-Myers Squibb) / Wydox (YSS)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
OxacillinInjection, solution1 g/50mLIntravenousBaxter Healthcare Corporation1989-10-26Not applicableUS flag
OxacillinInjection, solution2 g/50mLIntravenousBaxter Healthcare Corporation1989-10-26Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
OxacillinInjection, powder, for solution2 g/20mLIntramuscular; IntravenousMitim s.r.l.2017-07-31Not applicableUS flag
OxacillinInjection, powder, for solution2 g/2gIntramuscular; IntravenousPiramal Critical Care Inc2018-06-012022-08-01US flag
OxacillinInjection, powder, for solution2 g/1Intramuscular; IntravenousArmas Pharmaceuticals Inc.2022-09-21Not applicableUS flag
OxacillinInjection, powder, for solution1 g/1Intramuscular; IntravenousAGILA SPECIALTIES PRIVATE LIMITED2014-08-262017-09-01US flag
OxacillinInjection, powder, for solution1 g/1Intramuscular; IntravenousSandoz1976-01-06Not applicableUS flag

Categories

ATC Codes
J01CR50 — Combinations of penicillinsJ01CF04 — Oxacillin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Penicillins / N-acyl-alpha amino acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Thiazolidines / Heteroaromatic compounds / Isoxazoles / Secondary carboxylic acid amides / Azetidines / Thiohemiaminal derivatives
show 10 more
Substituents
Alpha-amino acid or derivatives / Alpha-dipeptide / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Azole / Benzenoid / Beta-lactam / Carbonyl group / Carboxamide group
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
penicillin (CHEBI:7809)
Affected organisms
  • Enteric bacteria and other eubacteria
  • Staphylococcus aureus

Chemical Identifiers

UNII
UH95VD7V76
CAS number
66-79-5
InChI Key
UWYHMGVUTGAWSP-JKIFEVAISA-N
InChI
InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1
IUPAC Name
(2S,5R,6R)-3,3-dimethyl-6-(5-methyl-3-phenyl-1,2-oxazole-4-amido)-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(C)ON=C1C1=CC=CC=C1)C(O)=O

References

General References
Not Available
Human Metabolome Database
HMDB0014851
KEGG Drug
D08307
KEGG Compound
C07334
PubChem Compound
6196
PubChem Substance
46505710
ChemSpider
5961
BindingDB
50350483
RxNav
7773
ChEBI
7809
ChEMBL
CHEMBL819
ZINC
ZINC000003875439
Therapeutic Targets Database
DAP000440
PharmGKB
PA450725
PDBe Ligand
105
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxacillin
MSDS
Download (38 KB)

Clinical Trials

Clinical Trials

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Apothecon inc div bristol myers squibb
  • Teva pharmaceuticals usa inc
  • Baxter healthcare corp
  • Apothecon sub bristol myers squibb co
  • Elkins sinn div ah robins co inc
  • Istituto biochimico italiano spa
  • Marsam pharmaceuticals llc
  • Sandoz inc
  • Watson laboratories inc
Packagers
  • Baxter International Inc.
  • Carlisle Laboratories Inc.
  • Dispensing Solutions
  • Mead Johnson and Co.
  • Physicians Total Care Inc.
  • Sandoz
  • SC Antibiotice SA
  • Teva Pharmaceutical Industries Ltd.
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Intravenous1 g
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous1 g
Injection, powder, for solutionIntravenous1 g
Injection, powder, for solutionIntravenous100000 g
Injection, powder, for solutionParenteral1 g
Injection, powder, for solutionIntramuscular; Intravenous100000 g
Injection, powder, for solutionIntramuscular; Intravenous1 g/20mL
Injection, powder, for solutionIntramuscular; Intravenous1 g/1g
Injection, powder, for solutionIntramuscular; Intravenous1 g/1
Injection, powder, for solutionIntramuscular; Intravenous2 g/2g
Injection, powder, for solutionIntramuscular; Intravenous2 g/1
Injection, powder, for solutionIntramuscular; Intravenous2 g/20mL
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, for solutionIntravenous10 g/100mL
Injection, powder, for solutionIntravenous10 g/10g
Injection, powder, for solutionIntravenous2 g/1
Injection, solutionIntravenous1 g/50mL
Injection, solutionIntravenous2 g/50mL
Powder, for solutionIntramuscular; Intravenous1 g/1
Powder, for solutionIntramuscular; Intravenous2 g/1
Powder, for solutionIntravenous10 g/100mL
Capsule250 MG
Injection, powder, for solutionIntramuscular1 g/5ml
Injection, powder, for solutionIntramuscular500 mg
Injection, powder, for solutionIntravenous1 g/5ml
Injection, powder, for solutionParenteral1 G/5ML
Injection, powder, for solutionParenteral250 MG/2ML
Injection, powder, for solutionParenteral500 MG
Prices
Unit descriptionCostUnit
Oxacillin 10 gm vial118.01USD each
Oxacillin 2 gm vial24.08USD each
Oxacillin 1 gm vial12.41USD each
Oxacillin 2 gm/ 50 ml inj0.62USD ml
Oxacillin 1 gm/ 50 ml inj0.43USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)188 °CPhysProp
water solubility13.9 mg/LNot Available
logP2.38HANSCH,C ET AL. (1995)
pKa2.72SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0862 mg/mLALOGPS
logP2.05ALOGPS
logP1.7Chemaxon
logS-3.7ALOGPS
pKa (Strongest Acidic)3.75Chemaxon
pKa (Strongest Basic)-0.12Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area112.74 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity101.83 m3·mol-1Chemaxon
Polarizability39.61 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.8002
Blood Brain Barrier-0.9923
Caco-2 permeable+0.7059
P-glycoprotein substrateNon-substrate0.6161
P-glycoprotein inhibitor INon-inhibitor0.867
P-glycoprotein inhibitor IINon-inhibitor0.922
Renal organic cation transporterNon-inhibitor0.9669
CYP450 2C9 substrateNon-substrate0.8181
CYP450 2D6 substrateNon-substrate0.8807
CYP450 3A4 substrateSubstrate0.5347
CYP450 1A2 substrateInhibitor0.5746
CYP450 2C9 inhibitorNon-inhibitor0.8725
CYP450 2D6 inhibitorNon-inhibitor0.9111
CYP450 2C19 inhibitorNon-inhibitor0.8665
CYP450 3A4 inhibitorNon-inhibitor0.665
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9564
Ames testNon AMES toxic0.7304
CarcinogenicityNon-carcinogens0.5273
BiodegradationNot ready biodegradable0.9759
Rat acute toxicity1.6583 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9997
hERG inhibition (predictor II)Non-inhibitor0.8773
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0006-9756000000-f6bf977e3f72e4a53daf
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0090000000-79c009ac45201875c809
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-1290000000-4d46550a2c9c9f77458a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-8890000000-4a47690fda1171ea9191
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00e9-9530000000-81bb9ec609f6a7e8c6dd
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00e9-9410000000-b5c01a94c4b433924722
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00e9-9200000000-4bfc7a848a77bc668c0a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01b9-9000000000-927fa2d2be3c33adb44c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9000000000-3661f69f0fee17d6a499
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9000000000-f568ba02b1720f9fd951
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dl-0980000000-62551643a67b5e9a21f8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dl-0920000000-69978fc6eeaa10c71f81
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0900000000-92b22bc2f96b5f612718
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-1900000000-4dceea173f6174da433d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-3900000000-3ee73f5cb610870dbdb1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ikj-9800000000-fbc9b294222787b35a80
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0k92-9200000000-a405a812cf5f1a2f17e1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udj-9100000000-451b59b916ee627de317
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-9000000000-21eb1aa369a09320f715
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0190100000-39d082eb1819979378db
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03xu-0960100000-cc6e87b344c8b3d402ba
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0091000000-b0d8ae6e2a9472c4a485
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-052f-8193100000-ca82d2bf50e1a5eb18a6
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-06ri-0900000000-a42d5dd4c6b4bca1e1a7
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001l-9667000000-788267aaacb38d3bdeb4
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-195.1190829
predicted
DarkChem Lite v0.1.0
[M-H]-197.0534829
predicted
DarkChem Lite v0.1.0
[M-H]-187.3972
predicted
DeepCCS 1.0 (2019)
[M+H]+198.6575829
predicted
DarkChem Lite v0.1.0
[M+H]+195.5941829
predicted
DarkChem Lite v0.1.0
[M+H]+189.79277
predicted
DeepCCS 1.0 (2019)
[M+Na]+195.6646829
predicted
DarkChem Lite v0.1.0
[M+Na]+195.70528
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Streptococcus pneumoniae
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Not Available
Gene Name
pbp3
Uniprot ID
Q75Y35
Uniprot Name
Penicillin-binding protein 3
Molecular Weight
45209.84 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring acyl groups
Specific Function
Not Available
Gene Name
pbp2a
Uniprot ID
Q8DNB6
Uniprot Name
Penicillin-binding protein 2a
Molecular Weight
80797.94 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Penicillin binding
Specific Function
Cell wall formation.
Gene Name
pbpA
Uniprot ID
Q8DR59
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
79700.9 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Not Available
Specific Function
Penicillin binding
Gene Name
penA
Uniprot ID
P0A3M6
Uniprot Name
Penicillin-binding protein 2B
Molecular Weight
73872.305 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring acyl groups
Specific Function
Not Available
Gene Name
pbp1b
Uniprot ID
Q7CRA4
Uniprot Name
Penicillin-binding protein 1b
Molecular Weight
89479.92 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Kind
Protein
Organism
Clostridium perfringens (strain 13 / Type A)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring glycosyl groups
Specific Function
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
Gene Name
pbpA
Uniprot ID
Q8XJ01
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
75176.35 Da
References
  1. Williamson R: Resistance of Clostridium perfringens to beta-lactam antibiotics mediated by a decreased affinity of a single essential penicillin-binding protein. J Gen Microbiol. 1983 Aug;129(8):2339-42. doi: 10.1099/00221287-129-8-2339. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
Kind
Protein
Organism
Staphylococcus aureus
Pharmacological action
Unknown
General Function
Penicillin binding
Specific Function
Not Available
Gene Name
mecA
Uniprot ID
D6R448
Uniprot Name
Penicillin-binding protein 2
Molecular Weight
10694.04 Da
References
  1. Chung M, Antignac A, Kim C, Tomasz A: Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. Antimicrob Agents Chemother. 2008 Aug;52(8):2709-17. doi: 10.1128/AAC.00266-08. Epub 2008 May 27. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G: Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping. Bioorg Med Chem. 2011 Aug 1;19(15):4544-51. doi: 10.1016/j.bmc.2011.06.027. Epub 2011 Jun 16. [Article]
Kind
Protein
Organism
Escherichia coli
Pharmacological action
Unknown
Actions
Substrate
General Function
Beta-lactamase activity
Specific Function
Has strong cefotaxime-hydrolyzing activity.
Gene Name
bla
Uniprot ID
Q47066
Uniprot Name
Beta-lactamase Toho-1
Molecular Weight
31446.6 Da
References
  1. Ishii Y, Ohno A, Taguchi H, Imajo S, Ishiguro M, Matsuzawa H: Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother. 1995 Oct;39(10):2269-75. [Article]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [Article]

Drug created at June 13, 2005 13:24 / Updated at April 19, 2024 20:16